Thaddeus Beck

9PUBLICATIONS
130CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Disease surveillanceMolecular targetsHealth and ecological risk assessmentPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Aug 24, 2026
Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE.

|Apr 10, 2026
Remote Therapeutic Monitoring and Infection-Related Health Care Resource Utilization in Patients With Hematologic Malignancies.

Benjamin A Derman, James H Essell, Mustafa S Ascha

|Dec 12, 2024
Sacituzumab Govitecan in Patients with Relapsed/Refractory Advanced Head and Neck Squamous Cell Carcinoma: Results from the Phase II TROPiCS-03 Basket Study.

Loren Michel, Antonio Jimeno, Ammar Sukari

|Sep 06, 2024
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.

Komal L Jhaveri, Elgene Lim, Rinath Jeselsohn

|May 01, 2024
A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation.

Rona Yaeger, Meredith A McKean, Rizwan Haq

|Jun 06, 2023
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.

Todd M Bauer, Kathleen N Moore, Janet S Rader

Pageof 2

Frequent Collaborators

2 joint publications

Seock-Ah Im

2 joint publications

Sung-Bae Kim

2 joint publications

Michael Kolodziej

2 joint publications

Philippe Aftimos